Zofran Lawsuits See Increase In Filing As GSK’s Marketing Tactics Create Public Controversies

March 29, 2016 – – ZofranLegal.com reports on new controversies surrounding Zofran lawsuits in Boston, Massachusetts, as parents from across the United States continue to file complaints against the anti-nausea drug manufacturer GlaxoSmithKline, claiming that exposure to the drug while developing in the womb caused unborn babies to develop a range of severe and sometimes fatal birth defects.

In March of 2016, parents filed a lawsuit against GSK in the U.S. District Court for the Western District Court of Louisiana, Lafayette Division, claiming that fetal exposure to Zofran caused their son to develop congenital heart defects while in utero. The boy’s mother was prescribed Zofran during her first trimester of pregnancy to treat morning sickness. While the first trimester is a common time to experience nausea and vomiting associated with morning sickness, it is also a time when the fetus does much of its initial heart, limb, and mouth tissue formation. The son was reportedly born in November of 2012 and at this time he was diagnosed with the heart defects, and his parents were informed that he required immediate heart surgery, as well as extensive follow-up treatment.

Unfortunately, these parents are not alone in their claims. From across the United States, more than 220 parents have stepped forward to date, alleging that their children, who were also exposed to Zofran while in utero, have developed birth defects, including: cleft lip and palate, atrial septal and ventricular septal defects, transposition of the greater vessels, kidney defects, club foot, and respiratory distress syndrome.

Plaintiffs involved in these lawsuits commonly note that the drug was marketed and prescribed “off-label.” This term means that the drug was never FDA-approved to treat pregnant women for morning sickness. Zofran was instead approved by the FDA to treat nausea and vomiting episodes among patients who have recently undergone radiation, chemotherapy, or anesthesia. Reportedly, however, pharmaceutical giant GSK went on to market the drug as a safe and effective treatment for expectant mothers going through morning sickness to OB/GYNs as well as the general public. This led to “off-label” prescriptions, which were reportedly given to over 1 million women during just one year’s time.

As these plaintiffs await trials, the attorneys of Monheit Law are working to assist any women who used Zofran while pregnant and who subsequently gave birth to children with defects. They want to ensure that these women are provided with the important opportunity to evaluate their legal rights in full. Affected mothers, families, and children may be entitled to significant compensation attained through legal action. To better assist those who wish to look further into their legal rights, the attorneys of Monheit Law are also currently offering free legal consultations for qualifying parties.

To request additional information on Zofran lawsuits, or to ask questions, please contact Attorney Michael Monheit, Lead Attorney of Monheit Law, by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60008953